Metabolic Disease Conference, Boston

Dear Muni The Metabolic Syndrome is a greater detriment than cancer to our society’s overall health. In order to address this problem, there has been an increasing effort to find solutions that prevent and reverse the Metabolic Syndrome. The 4th Metabolic Diseases World Summit, taking place on November 6-7, 2008 in Boston, MA, is devoted to better understanding new options in dealing with this condition. Speakers from both academia and industry will focus on the advances of treatments for Metabolic Diseases and how they relate to Insulin, Diabetes, Obesity, Cardiovascular Disease and Mitochondrial Function.Save up to up $300 by September 6, 2008! Register now! SEND YOUR TEAM...Register 2, and the 3rd person goes FREE! HIGHLIGHTS • Panel Discussions: - Partnering/Licensing in Metabolic Diseases - Regulatory Issues in Metabolic Disease Drug Development • Keynote Speeches: - Epidemiology and Medical Needs of the Metabolic Syndrome - FDA Regulations, Draft Guidelines, & Getting Therapies to Market Abstract Submissions:Submit an abstract for poster presentation and have the chance to give an oral presentation. Deadline is October 6, 2008. Click here for submission. UPCOMING EVENTS Protein Therapeutics Discovery & Development September 8-9, 2008 San Diego, CA Bugs & Drugs September 22-23, 2008 San Diego, CA Global Clinical Trial Operations September 25-26, 2008 San Diego, CA Biomarker Discovery EuropeOct. 2-3, 2008 Dublin, Ireland10% discount by Sept 2 4th Neurodegenerative Diseases Drug Discovery Oct. 9-10, 2008 San Francisco, CA10% discount by Sept 9 4th Modern Drug Discovery and Development Summit6 Full Tracks 3 Short Symposia 6 Study SessionsOct. 15-17, 2008 San Diego, CA Advances in Stem Cell Discoveries Oct. 27-28, 2008 San Francisco, CA10% discount by Sept 27 4th Metabolic Diseases World Summit Nov. 6-7, 2008 Boston, MA20% discount by Sept 6 6th Vaccines: All Things Considered Nov. 13-14, 2008 Washington, DC20% discount by Sept 12 PROGRAM HIGHLIGHTS Metabolic Syndrome: Delaying CVD and Type 2 Diabetes • Risk Factors and Complications: Hyperglycemia, Insulin Resistance and Cardiovascular Diseases• Current Treatments to Reduce Cardiovascular Risks• Current Treatments of Type 2 Diabetes (including Insulin Sensitizers): What Has Worked and What are the Unmet Needs? Obesity: New Therapeutic Targets • MCHR-1• 11-Beta – HSD - Incyte Obesity Drug Therapies• SCD1• Ghrelin Antagonists• AMPK - Obesity and DiabetesDiabetes: New Therapeutic Targets • GLP-1 Analogs• GPR – 119 – H Overton Prosidion• Glucokinase Activators• SGLT2• DPPIV Inhibitors• FGF21• Sirt1• Mitochondrial Dysfunction and Diabetes• Endoplasmic Reticulum Stress and Diabetes Obesity: Drug Development • Obesity Drug Therapies Orexigen (Contrave and Empatic Phase III and II), Arena (Lorcaserin Phase III), Neurosearch (Tesofensin Phase IIb), (Taranabant)• Combination Drug Therapies vs. Single Drug Therapies• CBI Antagonists Rimonabant Diabetes: Drug Development • Strengths and Weaknesses of Current and Existing Drugs• Anti-Diabetic Drugs in Development• Avandia Cardiovascular Safety Data• SGLT2• GKAs• GLP-1 Analogs – Byetta LAR Data • The Success of Januvia Development• The Failure of the Torcetrapib Development on Potential MOAs [FULL AGENDA] DISTINGUISHED PRESENTERS & ADVISORS Ganesh Bhat, Group Leader, Genomics Inst.of the Novartis Res. Fdn. Brad Geddes, Director, Elixir Pharmaceuticals, Inc. Joe Grimsby, Senior Research Leader, RocheYanglin He, Research Scientist, Novartis Timothy Herpin, Assoc. Dir., Scientific Licensing, Bristol-Myers SquibbMike Jirousek, CSO, Catabasis Pharmaceuticals, Inc.Sotirios Karathanasis, Vice President, Bioscience, AstraZenecaAlex Kharontonnekov, Research Advisor, bioTDR, Eli Lilly & Co. Yang Li, Research Scientist, Amgen John Mayer, Senior Research Advisor, Eli Lilly & Co. Michael McCully, Director & Senior Analyst, Recombinant Capital Ram Pillarisetti, Vice President of Research, Reddy US TherapeuticsCristina Rondinone, Director, Research Metabolic Diseases, RocheMing Wang, Scientific Director, Amgen Bernice Welles, Vice President Development, DIObexRuojing Yang, Senior Research Biologist, Merck & Co. Inc. [Speaker List] For Business Development & Exhibiting opportunities, contact Josette Barba at 626-256-6405 x105 or via email at josette.barba@gtcbio.com